Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

OCEANIC-STROKE shows asundexian cuts ischemic stroke recurrence by 26% in patients taking standard antiplatelet therapy, with no major bleeding increase. New stroke breakthroughs spotlight faster ...

View the basic RXRX option chain and compare options of Recursion Pharmaceuticals, Inc. on Yahoo Finance.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...